Valeant Wins Obagi

Ring up another “win” for Valeant!

| More on:
The Motley Fool

A couple of weeks ago Valeant Pharmaceuticals (TSX:VRX,NYSE:VRX) announced a $343.8 million ($19.75/share) bid for Obagi Medical Products (NASDAQ:OMPI).  Obagi was to become Valeant’s 21st acquisition since the beginning of 2011.

Last week a wrench was thrown into Valeant’s plans however when a German-based rival, Merz Pharma, stepped up with a $22/share bid for Obagi.  Game on!

There was some question of whether or not Valeant would bump its bid given the company’s historical tendency to acquire assets in the 2-2.5x sales range.  The Merz bid set the sales multiple at 3.2x for Obagi.

The next day however, April 3rd, Valeant did as any good serial acquirer would do and stepped up the bid to $24, which implied a 3.5x sales multiple.

Today, Merz indicated that their $22/share bid was their one and only and Obagi was all Valeant’s.

Obagi shares had been trading north of Valeant’s $24 bid and have pulled back, signifying the market’s belief that no further bidders will emerge.  Valeant shares were relatively flat on the day.

Foolish Takeaway

The Merz bid cost Valeant an extra $74 million or so to secure Obagi.  Valeant has the financial capacity to handle this bump but one of the big risks for this company, given its penchant for acquisitions, is that at some point it takes on a deal that it doesn’t have the financial capacity to handle.  Valeant has taken on significant debt to fuel its acquisition based growth strategy and if it gets into a bidding war for a more significant asset at some point down the line, financial issues may be part of this firm’s future.

Valeant’s balance sheet and penchant for acquisitions is a tad scary.  In my mind, dividends are a much more shareholder friendly use of a company’s capital and we’ve identified 13 U.S. companies that will have you rolling in dividend cheques before you know it.  Simply click here and we’ll send you “13 High Yielding Stocks to Buy Today” – absolutely FREE!  You’re just one click away from dividend nirvana!

Follow us on Twitter and Facebook for the latest in Foolish investing.

Fool contributor Iain Butler does not own shares in any of the companies mentioned in this report at this time.  The Motley Fool has no positions in the stocks mentioned above.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing


3 Stocks to Buy and Hold for Total Returns

For investors seeking excellent total returns over the long haul, here are three Canadian stocks to buy before the market…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.

3 Defensive Stocks That Cautious Investors Can Feel Confident Buying

Consider buying Fortis (TSX:FTS) and other defensive dividend stocks in 2024.

Read more »

healthcare pharma
Stocks for Beginners

2 Healthcare Stocks You Can Buy and Hold for the Next Decade

These two healthcare stocks are showing strong signs of growth for the next decade and are already improving by leaps…

Read more »

analyze data
Tech Stocks

If You’d Invested $500 in Nuvei Stock in 2020, This Is How Much You Would Have Today

Nuvei (TSX:NVEI) stock has seen its shares climb to triple digits and fall below IPO prices. So, what now for…

Read more »

Is Nvidia stock a buy?
Tech Stocks

Is Nvidia Stock a Buy After Its Huge Post-Earnings Surge?

Nvidia (Nasdaq:NVDA) stock jumped after the company’s phenomenal fourth-quarter earnings report, and everyone’s talking about a booming future for AI.…

Read more »

Man data analyze
Dividend Stocks

1 Recession-Resistant Stock to Buy and Hold Forever

Brookfield Renewable is a recession-resistant high dividend stock trading at a cheap valuation in 2024.

Read more »

Bank Stocks

Is TD Bank Stock a Buy Now After Solid Earnings?

TD deserves to be on your radar today.

Read more »

potted green plant grows up in arrow shape
Dividend Stocks

3 Hypergrowth Stocks to Buy in 2024 and Beyond

There are stocks growing, and there are stocks hitting all-time highs. These are three that I would therefore consider on…

Read more »